HealthMore in Health→
Replimune’s second FDA rejection keeps pressure on biotech regulation and cancer drug risk
Key Takeaways
- Replimune’s skin cancer drug was reportedly rejected by the FDA for a second time.
- The case had already become a flashpoint in FDA debates.
- The outcome highlights ongoing regulatory risk for biotech companies built around single major programs.
DE
DT Editorial Team··via statnews.com